Table 2 SCr levels in the LTE and Phase 3 studies: stabilization of SCr levels in the LTE studies
SCr increase at EoT in Phase 3 (%) | Mean (%) increase from baseline at EoT in index study, mg/dl | Mean (%) increase from baseline at last observed visit in LTE, mg/dl |
|---|---|---|
≤10% (n = 909) | 0.00 (0.3) | 0.05 (7.5) |
>10 to <33% (n = 653) | 0.13 (18.6) | 0.13 (18.5) |
≥33 to ≤50% (n = 82) | 0.25 (38.2) | 0.24 (36.5) |
>50% (n = 7) | 0.32 (56.0) | 0.26 (44.9) |